| 臺大學術典藏 |
2021-10-14T02:45:23Z |
Effect of diabetes mellitus and glycemic control on the prognosis of non-muscle invasive bladder cancer: a retrospective study
|
Huang W.-L.; Huang K.-H.; CHAO-YUAN HUANG; Pu Y.-S.; Chang H.-C.; Chow P.-M. |
| 臺大學術典藏 |
2021-10-14T02:45:22Z |
Polymorphism of nucleotide binding domain-like receptor protein 3 (NLRP3) increases susceptibility of total urinary arsenic to renal cell carcinoma
|
Chung C.-J.; Bao B.-Y.; Lin Y.-C.; Huang Y.-L.; Shiue H.-S.; Ao P.-L.; Pu Y.-S.; CHAO-YUAN HUANG; Hsueh Y.-M. |
| 臺大學術典藏 |
2021-10-14T02:45:22Z |
Preoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy
|
Cheng Y.-T.; CHAO-YUAN HUANG; Chen C.-H.; Chiu S.-T.; Hong J.-H.; Pu Y.-S.; Liu S.-P.; Lu Y.-C.; Chang Y.-K.; Chang H.-C.; Huang K.-H.; Lee Y.-J.; Chow P.-M.; Chiang I.-N.; Hung S.-C.; Chiang C.-H. |
| 臺大學術典藏 |
2021-10-14T02:45:21Z |
Effect of plasma selenium, red blood cell cadmium, total urinary arsenic levels, and eGFR on renal cell carcinoma
|
Hsueh Y.-M.; Lin Y.-C.; Huang Y.-L.; Shiue H.-S.; Pu Y.-S.; CHAO-YUAN HUANG; Chung C.-J. |
| 臺大學術典藏 |
2021-10-14T02:45:20Z |
Additive effects of arsenic and aristolochic acid in chemical carcinogenesis of upper urinary tract urothelium
|
Chen C.-H.; Grollman A.P.; CHAO-YUAN HUANG; Shun C.-T.; Sidorenko V.S.; Hashimoto K.; Moriya M.; Turesky R.J.; Yun B.H.; Tsai K.; Wu S.; Chuang P.-Y.; Tang C.-H.; Yang W.-H.; Tzai T.-S.; Tsai Y.-S.; Dickman K.G.; Pu Y.-S. |
| 臺大學術典藏 |
2021-10-14T02:45:20Z |
Outcomes of stratified transurethral resection of bladder tumor: A propensity score-matched analysis
|
Huang W.-L.; CHAO-YUAN HUANG; Huang K.-H.; Pu Y.-S.; Chang H.-C.; Chow P.-M. |
| 臺大學術典藏 |
2021-10-14T02:45:18Z |
Outcomes and prediction models for exclusive prostate bed salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy
|
Tseng C.-S.; Wang Y.-J.; Chen C.-H.; Wang S.-M.; Huang K.-H.; Chow P.-M.; Pu Y.-S.; CHAO-YUAN HUANG; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-09-04T06:24:13Z |
Antiandrogen hepatotoxicity in patients with chronic viral hepatitis
|
Pu Y.-S.; Liu C.-M.; JIA-HORNG KAO; Chen J.; Lai M.-K. |
| 臺大學術典藏 |
2021-09-01T02:02:46Z |
Use of retinoic acids in the treatment of peripheral T-cell lymphoma: A pilot study
|
ANN-LII CHENG; Su I.-J.; Chen C.-C.; Tien H.-F.; Lay J.-D.; Chen B.-R.; Pu Y.-S.; Hong R.-L.; Shen M.-C.; Wang C.-H.; Chen Y.-C. |
| 臺大學術典藏 |
2021-09-01T02:02:44Z |
Tamoxifen Enhances the Chemosensitivity of Bladder Carcinoma Cells
|
Pu Y.-S.; Hsieh T.-S.; Tsai T.-C.; ANN-LII CHENG; Hsieh C.-Y.; Su I.-J.; Lai M.-K. |
| 臺大學術典藏 |
2021-09-01T02:02:43Z |
Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: A potential use in intravesical chemotherapy
|
Pu Y.-S.; Hsieh T.-S.; ANN-LII CHENG; Tseng N.-F.; Su I.-J.; Hsieh C.-Y.; Lai M.-K.; Tsai T.-C. |
| 臺大學術典藏 |
2021-09-01T02:02:43Z |
Expression of mdr-1 gene in transitional cell carcinoma and its correlation with chemotherapy response
|
Pu Y.-S.; Tsai T.-C.; ANN-LII CHENG; Tsai C.-Y.; Tseng N.-F.; Su I.H.-J.; Hsieh C.-Y.; Lai M.-K. |
| 臺大學術典藏 |
2021-09-01T02:02:35Z |
Megestrol acetate antagonizes cisplatin cytotoxicity
|
Pu Y.-S.; ANN-LII CHENG; Chen J.; Guan J.-Y.; Lu S.-H.; Lai M.-K.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-09-01T02:02:30Z |
Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma
|
Hsu C.-H.; Chen J.; Wu C.-Y.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:30Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Lin C.-C.; Hsu C.-H.; Chen J.; Tsai T.-C.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:20Z |
Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells
|
Pu Y.-S.; Hour T.-C.; Chuang S.-E.; ANN-LII CHENG; Lai M.-K.; Kuo M.-L. |
| 臺大學術典藏 |
2021-09-01T02:02:11Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; ANN-LII CHENG; Chen J.; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:09Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; ANN-LII CHENG; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:06Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:32Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Lin C.-C.; Hsu C.-H.; Hour T.-C.; ANN-LII CHENG; Huang C.-Y.; Huang K.-H.; Chen J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:27Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Lin C.-C.; Pu Y.-S.; Hsu C.-H.; Keng H.-Y.; ANN-LII CHENG; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:19Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; Tsai Y.-C.; Hsu F.-M.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:53:49Z |
Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma
|
Tsai Y.-C.; Yeh C.-H.; Tzen K.-Y.; Ho P.-Y.; Tuan T.-F.; Pu Y.-S.; ANN-LII CHENG; Cheng J.C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:51Z |
Synergistic blockade of EGFR and HER2 by new-generation EGFR tyrosine kinase inhibitor enhances radiation effect in bladder cancer cells
|
Tsai Y.-C.; Ho P.-Y.; Tzen K.-Y.; Tuan T.-F.; Liu W.-L.; ANN-LII CHENG; Pu Y.-S.; Cheng J.C.-H. |
